Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22260008,retention times,"The average retention times of gemfibrozil and tashinone II(A) were 10.5 and 14.5 min, respectively.",[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),min,10.5,301,DB01241,Gemfibrozil
,22260008,retention times,"The average retention times of gemfibrozil and tashinone II(A) were 10.5 and 14.5 min, respectively.",[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),min,14.5,302,DB01241,Gemfibrozil
,22260008,half-life,The half-life was prolonged from 2. 573 h of free tashinone II(A) to 4. 117 h and MRT(0-infinity) from 2.585 h to 6.033 h.,[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),h,2. 573,303,DB01241,Gemfibrozil
,22260008,half-life,The half-life was prolonged from 2. 573 h of free tashinone II(A) to 4. 117 h and MRT(0-infinity) from 2.585 h to 6.033 h.,[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),h,4. 117,304,DB01241,Gemfibrozil
,22260008,MRT(0-infinity),The half-life was prolonged from 2. 573 h of free tashinone II(A) to 4. 117 h and MRT(0-infinity) from 2.585 h to 6.033 h.,[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),h,2.585,305,DB01241,Gemfibrozil
,22260008,MRT(0-infinity),The half-life was prolonged from 2. 573 h of free tashinone II(A) to 4. 117 h and MRT(0-infinity) from 2.585 h to 6.033 h.,[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),h,6.033,306,DB01241,Gemfibrozil
,22260008,max concentration,The max concentration of tashinone II(A) was reduced from 0.21 to 0.134 mg/L.,[Study on the pharmacokinetics of tashinone II(A) -loaded polylactic acid nanoparticles in rabbit]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22260008/),[mg] / [l],0,307,DB01241,Gemfibrozil
,10991959,hepatic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],10.4,727,DB01241,Gemfibrozil
,10991959,apparent intrinsic clearance,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,728,DB01241,Gemfibrozil
,10991959,hepatic extraction ratio,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),[ml] / [min],94.1,729,DB01241,Gemfibrozil
,10991959,biliary excretion half-life,"Mean +/- S. D. hepatic clearance, apparent intrinsic clearance, hepatic extraction ratio, and biliary excretion half-life of GG were 10.4 +/- 1.4 ml/min, 94.1 +/- 17.9 ml/min, 0.346 +/- 0.046, and 30.9 +/- 4.9 min, respectively, and approximately 73% of GG was excreted into bile.","Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-beta-D-glucuronide: effects of clofibric acid, acetaminophen, and acetaminophen glucuronide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10991959/),min,30.9,730,DB01241,Gemfibrozil
,15900286,elimination half-life (t (1/2) ),"Gemfibrozil alone raised the mean total area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of pioglitazone 3.2-fold (range, 2.3-fold to 6.5-fold; P < .001) and prolonged its elimination half-life (t (1/2) ) from 8.3 to 22.7 hours ( P < .001) but had no significant effect on its peak concentration (C max ) compared with placebo (control).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900286/),h,8.3 to 22.7,4948,DB01241,Gemfibrozil
,21646435,oral bioavailability,"Raloxifene is extensively glucuronidated in humans, effectively reducing its oral bioavailability (2%).",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),%,2,11527,DB01241,Gemfibrozil
,21646435,hepatic availability,"In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine.",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),,0.63,11528,DB01241,Gemfibrozil
,21646435,hepatic availability,"In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine.",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),,0.43,11529,DB01241,Gemfibrozil
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),nM,0.0676,17157,DB01241,Gemfibrozil
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,14.2,17158,DB01241,Gemfibrozil
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),μM,5.48,17159,DB01241,Gemfibrozil
,23139378,inhibition constants,"The plasma concentration profiles of repaglinide were well reproduced by the PBPK model based on the above assumptions, and the optimized values for the inhibition constants (0.0676 nM for itraconazole against CYP3A4; 14.2 μM for gemfibrozil against OATP1B1; and 5.48 μM for gemfibrozil glucuronide against OATP1B1) and the fraction of repaglinide metabolized by CYP2C8 (0.801) were consistent with the reported values.",Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23139378/),,0.,17160,DB01241,Gemfibrozil
,16838266,flow gradient,"The chromatographic run time was less than 20 min using flow gradient (0.0-1.60 mL/min) with a mobile phase consisting of 0.01 M ammonium acetate:acetonitrile:methanol (50:40:10, v/v/v) and UV detection at 275 nm.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),[ml] / [min],0.0-1.60,22411,DB01241,Gemfibrozil
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,6.7,22412,DB01241,Gemfibrozil
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,13.9,22413,DB01241,Gemfibrozil
,16838266,Nominal retention times,"Nominal retention times of RST, GFZ and IS were 6.7, 13.9 and 16.4 min, respectively.",Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),min,16.4,22414,DB01241,Gemfibrozil
greater,16838266,Absolute recovery,Absolute recovery of both analytes and IS was greater than 90%.,Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16838266/),%,90,22415,DB01241,Gemfibrozil
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,72,24500,DB01241,Gemfibrozil
,15194707,IC(50),"Uptake studies showed that GEM and GEM-1-O-glu significantly inhibited the OATP2-mediated uptake of CER with IC(50) values of 72 and 24 microM, respectively.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,24,24501,DB01241,Gemfibrozil
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,28,24502,DB01241,Gemfibrozil
,15194707,IC(50),"They also inhibited the CYP2C8-mediated metabolism of CER with IC(50) values of 28 and 4 microM, respectively, whereas M3 had no effects.",Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15194707/),μM,4,24503,DB01241,Gemfibrozil
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],3.20,28337,DB01241,Gemfibrozil
,10976543,peak concentration,"The peak concentration of simvastatin acid was increased by 112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P < .01).",Plasma concentrations of active simvastatin acid are increased by gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976543/),[ng] / [ml],6.78,28338,DB01241,Gemfibrozil
,30335192,Cmax ratios,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.01-2.05,33112,DB01241,Gemfibrozil
,30335192,AUC ratio,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.04-2.23,33113,DB01241,Gemfibrozil
,30335192,Cmax ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33114,DB01241,Gemfibrozil
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33115,DB01241,Gemfibrozil
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.41,33116,DB01241,Gemfibrozil
,22173280,AUC₀₋₁₂,"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"2,167",35558,DB01241,Gemfibrozil
,22173280,AUC₀₋₁₂,"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"2,970",35559,DB01241,Gemfibrozil
,22173280,AUC(0-∞),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"3,621",35560,DB01241,Gemfibrozil
,22173280,AUC(0-∞),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[h·ng] / [ml],"5,574",35561,DB01241,Gemfibrozil
,22173280,C(max),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[ng] / [ml],282.9,35562,DB01241,Gemfibrozil
,22173280,C(max),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),[ng] / [ml],344.1,35563,DB01241,Gemfibrozil
,22173280,t(½),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),h,7.4,35564,DB01241,Gemfibrozil
,22173280,t(½),"Relative to the administration of sitagliptin alone, co-administration with gemfibrozil increased the AUC₀₋₁₂ (2,167 ± 82.9 vs. 2,970 ± 76.4 ng h/ml; p < 0.0001), AUC(0-∞) (3,621 ± 222.5 vs. 5,574 ± 249.6 ng h/ml; p < 0.0002), C(max) (282.9 ± 7.7 vs. 344.1 ± 5.9 ng/ml; p < 0.0001), and t(½) (7.4 ± 0.6 vs. 10 ± 0.6 h; p = 0.0076) to statistically significant levels.",Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173280/),h,10,35565,DB01241,Gemfibrozil
,11451637,detection limit,The detection limit of this method was 0.025 microg ml(-1); only 0.5 ml of the plasma sample was required for the determination.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),[μg] / [ml],0.025,39135,DB01241,Gemfibrozil
,11451637,recoveries,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,90.15,39136,DB01241,Gemfibrozil
<,11451637,C.V.'s,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,8,39137,DB01241,Gemfibrozil
,11451637,C.V.'s,Mean recoveries were of 90.15+/-6.9% (C.V.'s<8%) for gemfibrozil and 93.10% for ibuprofen Applicability of the method was demonstrated by a pharmacokinetic study in normal volunteers who received gemfibrozil by oral route.,A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11451637/),%,93.10,39138,DB01241,Gemfibrozil
,9082840,relative bioavailability,The relative bioavailability of Innogem with respect to Lopid 300 mg capsule for AUC0-infinity was 104.06 +/- 21.61%.,[Bioanalysis of gemfibrozil. Comparative human pharmacokinetics of 300 mg of gemfibrozil-containing Innogem and Lopid capsules]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9082840/),%,104.06,48743,DB01241,Gemfibrozil
,2303577,AUC,"However, when colestipol was given with gemfibrozil, there was a decrease in AUC (43.6 +/- 21.9 mg*hr/L) compared with gemfibrozil given alone (62.6 +/- 10.3 mg*hr/L) which was statistically different by both ANOVA and paired t-test.",Apparent reduced absorption of gemfibrozil when given with colestipol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303577/),[h·mg] / [l],43.6,51304,DB01241,Gemfibrozil
,2303577,AUC,"However, when colestipol was given with gemfibrozil, there was a decrease in AUC (43.6 +/- 21.9 mg*hr/L) compared with gemfibrozil given alone (62.6 +/- 10.3 mg*hr/L) which was statistically different by both ANOVA and paired t-test.",Apparent reduced absorption of gemfibrozil when given with colestipol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303577/),[h·mg] / [l],62.6,51305,DB01241,Gemfibrozil
,2303577,Cmax,Cmax when colestipol was given with gemfibrozil (14.7 +/- 6.6 mg/L) was not statistically different from gemfibrozil alone (20.1 +/- 4.9 mg/L).,Apparent reduced absorption of gemfibrozil when given with colestipol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303577/),[mg] / [l],14.7,51306,DB01241,Gemfibrozil
,2303577,Cmax,Cmax when colestipol was given with gemfibrozil (14.7 +/- 6.6 mg/L) was not statistically different from gemfibrozil alone (20.1 +/- 4.9 mg/L).,Apparent reduced absorption of gemfibrozil when given with colestipol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303577/),[mg] / [l],20.1,51307,DB01241,Gemfibrozil
,32857315,terminal elimination half-life (t1/2),The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),h,20-22,66946,DB01241,Gemfibrozil
,32857315,t1/2,The mean terminal elimination half-life (t1/2) for ozanimod was approximately 20-22 h while the mean t1/2 for CC112273 and CC1084037 were approximately 10 days.,"Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32857315/),d,10,66947,DB01241,Gemfibrozil
,20592724,half-maximal inhibitory concentration (IC(50)),"In human liver microsomes, gemfibrozil 1-O-beta glucuronide inhibited the formation of M6 (but not of M5) from montelukast 35-fold more potently than did gemfibrozil (half-maximal inhibitory concentration (IC(50)) 3.0 and 107 micromol/l, respectively).",Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592724/),[μM] / [l],3.0,67632,DB01241,Gemfibrozil
,20592724,half-maximal inhibitory concentration (IC(50)),"In human liver microsomes, gemfibrozil 1-O-beta glucuronide inhibited the formation of M6 (but not of M5) from montelukast 35-fold more potently than did gemfibrozil (half-maximal inhibitory concentration (IC(50)) 3.0 and 107 micromol/l, respectively).",Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592724/),[μM] / [l],107,67633,DB01241,Gemfibrozil
,26195223,kinact,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70604,DB01241,Gemfibrozil
,26195223,K'app,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70605,DB01241,Gemfibrozil
,26195223,maximum inactivation rate constant,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.071,70606,DB01241,Gemfibrozil
,26195223,apparent dissociation constant,"We estimated the kinact and K'app values, which are the maximum inactivation rate constant and the apparent dissociation constant, of gemfibrozil to be 0.071 min(-1) and 57.3 μM, respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),μM,57.3,70607,DB01241,Gemfibrozil
,26195223,kobs,"The kobs, in vivo values of potent mechanism-based inhibitors, clarithromycin and erythromycin, were estimated to be 0.0096 min(-1) and 0.0051 min(-1), respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0096,70608,DB01241,Gemfibrozil
,26195223,kobs,"The kobs, in vivo values of potent mechanism-based inhibitors, clarithromycin and erythromycin, were estimated to be 0.0096 min(-1) and 0.0051 min(-1), respectively.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0051,70609,DB01241,Gemfibrozil
,26195223,kobs,"The kobs, in vivo value of gemfibrozil was 0.0060 min(-1), which was comparable to those of clarithromycin and erythromycin, suggesting that gemfibrozil could be a mechanism-based inhibitor as potent as clarithromycin and erythromycin in vivo.",Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195223/),1/[min],0.0060,70610,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),[μg] / [ml],0.530,72413,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),[μg] / [ml],13.25,72414,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,132.5,72415,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,265.0,72416,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,72.2,72417,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,87.9,72418,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,90.4,72419,DB01241,Gemfibrozil
,19309757,recovery,"The recovery for plasma samples of 0.530, 13.25, 132.5 and 265.0 microg/mL was 72.2, 87.9, 90.4 and 94.7%, respectively.",High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19309757/),%,94.7,72420,DB01241,Gemfibrozil
,12898007,elimination half-life (t(1/2)),Gemfibrozil raised the mean area under the plasma rosiglitazone concentration-time curve (AUC) 2.3-fold (range 1.5- to 2.8-fold; p=0.00002) and prolonged the elimination half-life (t(1/2)) of rosiglitazone from 3.6 to 7.6 h ( p=0.000002).,Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,3.6,76726,DB01241,Gemfibrozil
,12898007,elimination half-life (t(1/2)),Gemfibrozil raised the mean area under the plasma rosiglitazone concentration-time curve (AUC) 2.3-fold (range 1.5- to 2.8-fold; p=0.00002) and prolonged the elimination half-life (t(1/2)) of rosiglitazone from 3.6 to 7.6 h ( p=0.000002).,Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,7.6,76727,DB01241,Gemfibrozil
,12898007,t(max),"In addition, gemfibrozil prolonged the t(max) of N-desmethylrosiglitazone from 7 to 12 h and reduced the N-desmethylrosiglitazone/rosiglitazone AUC(0-48) ratio by 38% ( p<0.01).",Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,7,76728,DB01241,Gemfibrozil
,12898007,t(max),"In addition, gemfibrozil prolonged the t(max) of N-desmethylrosiglitazone from 7 to 12 h and reduced the N-desmethylrosiglitazone/rosiglitazone AUC(0-48) ratio by 38% ( p<0.01).",Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12898007/),h,12,76729,DB01241,Gemfibrozil
,26169402,maximal relative efficacy (E max),"GSK1322322 demonstrated a uniform activity against the intracellular forms of all S. aureus strains tested, disregarding their resistance phenotypes, with a maximal relative efficacy (E max) of a 0.5 to 1 log10 CFU decrease compared to the original inoculum within 24 h and a static concentration (C s) close to its MIC in broth.",Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26169402/),cfu,0.5 to 1,77391,DB01241,Gemfibrozil
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼1.1,92275,DB01241,Gemfibrozil
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.014,92276,DB01241,Gemfibrozil
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼0.3,92277,DB01241,Gemfibrozil
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.007,92278,DB01241,Gemfibrozil
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,11.,108340,DB01241,Gemfibrozil
,16758263,elimination half-life (t(1/2)),"Itraconazole raised the peak plasma loperamide concentration (Cmax) 2.9-fold (range, 1.2-5.0; P < 0.001) and the total area under the plasma loperamide concentration-time curve (AUC(0-infinity)) 3.8-fold (1.4-6.6; P < 0.001) and prolonged the elimination half-life (t(1/2)) of loperamide from 11.9 to 18.7 h (P < 0.001).","Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,18,108341,DB01241,Gemfibrozil
,16758263,t(1/2),Gemfibrozil raised the Cmax of loperamide 1.6-fold (0.9-3.2; P < 0.05) and its AUC(0-infinity) 2.2-fold (1.0-3.7; P < 0.05) and prolonged its t(1/2) to 16.7 h (P < 0.01).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,16.7,108342,DB01241,Gemfibrozil
,16758263,t(1/2),The combination of itraconazole and gemfibrozil raised the Cmax of loperamide 4.2-fold (1.5-8.7; P < 0.001) and its AUC(0-infinity) 12.6-fold (4.3-21.8; P < 0.001) and prolonged the t(1/2) of loperamide to 36.9 h (P < 0.001).,"Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16758263/),h,36.9,108343,DB01241,Gemfibrozil
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],25,108570,DB01241,Gemfibrozil
,12811363,renal clearance,"The renal clearance of pravastatin was reduced from 25 L/h to 14 L/h by gemfibrozil (P <.0001), but the cumulative excretion of pravastatin into urine did not change significantly.",Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12811363/),[l] / [h],14,108571,DB01241,Gemfibrozil
,22538270,K(I),"In human hepatocytes and/or liver microsomes, gemfibrozil potently inhibited the hydroxylation of BRV-AC into BRV-OHAC (K(I) 12 μM) while having a marginal effect on BRV-OH formation (K(I) ≥153 μM).",Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538270/),μM,12,123395,DB01241,Gemfibrozil
≥,22538270,K(I),"In human hepatocytes and/or liver microsomes, gemfibrozil potently inhibited the hydroxylation of BRV-AC into BRV-OHAC (K(I) 12 μM) while having a marginal effect on BRV-OH formation (K(I) ≥153 μM).",Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538270/),μM,153,123396,DB01241,Gemfibrozil
>,22538270,K(I),Gemfibrozil-1-O-β-glucuronide had no relevant effect on either reaction (K(I) >200 μM).,Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22538270/),μM,200,123397,DB01241,Gemfibrozil
,15116058,inhibition constant,The in vitro results indicate that the maximum gemfibrozil inhibition of rosuvastatin OATP2-mediated uptake was 50%; the inhibition constant for the inhibitory process was 4.0 +/- 1.3 micromol/L.,The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116058/),[μM] / [l],4.0,131878,DB01241,Gemfibrozil
,9368706,bioavailability,The poor bioavailability (3-4%) and low volume of distribution of the compound LM-1554 suggest the gastrointestinal tract as the site of action for the antihyperlipaemic activity.,"Mechanism of the antihyperlipaemic activity and pharmacokinetics of 2-chloromethyl-5,6,7,8-tetrahydrobenzo(b)thieno[2,3-d]pyrimidin-4(3H)-o ne. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9368706/),%,3-4,134843,DB01241,Gemfibrozil
,9296277,relative bioavailability,The relative bioavailability of the test preparation with respect to the reference preparation in terms of the AUC0-oc was 104.06 +/- 21.61%.,Pharmacokinetic and bioequivalence study of two gemfibrozil preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296277/),%,104.06,136388,DB01241,Gemfibrozil
,11164856,residence times,"The residence times (in minutes) of 3H-TO and 14C-CO of hypertriglyceridemics were roughly twice the values of normolipidemics, i.e. 8.0 (5.5; 12.0) versus 15.0 (11.0; 24.0) and 21.5 (14.0; 33.0) versus 44.0 (32.0; 72.0), P=0.001.",The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164856/),min,8.0,137570,DB01241,Gemfibrozil
,11164856,residence times,"The residence times (in minutes) of 3H-TO and 14C-CO of hypertriglyceridemics were roughly twice the values of normolipidemics, i.e. 8.0 (5.5; 12.0) versus 15.0 (11.0; 24.0) and 21.5 (14.0; 33.0) versus 44.0 (32.0; 72.0), P=0.001.",The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164856/),min,15.0,137571,DB01241,Gemfibrozil
,11164856,residence times,"The residence times (in minutes) of 3H-TO and 14C-CO of hypertriglyceridemics were roughly twice the values of normolipidemics, i.e. 8.0 (5.5; 12.0) versus 15.0 (11.0; 24.0) and 21.5 (14.0; 33.0) versus 44.0 (32.0; 72.0), P=0.001.",The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164856/),min,21.5,137572,DB01241,Gemfibrozil
,11164856,residence times,"The residence times (in minutes) of 3H-TO and 14C-CO of hypertriglyceridemics were roughly twice the values of normolipidemics, i.e. 8.0 (5.5; 12.0) versus 15.0 (11.0; 24.0) and 21.5 (14.0; 33.0) versus 44.0 (32.0; 72.0), P=0.001.",The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11164856/),min,44.0,137573,DB01241,Gemfibrozil
,29779093,absolute bioavailability,Finerenone absolute bioavailability was 43.5% due to first-pass metabolism in the gut wall and liver.,"Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),%,43.5,144528,DB01241,Gemfibrozil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,3.48,144529,DB01241,Gemfibrozil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,2.70,144530,DB01241,Gemfibrozil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,1.10,144531,DB01241,Gemfibrozil
,26663350,IC50 values,"Gemfibrozil and gemfibrozil 1-O-β glucuronide inhibited the cellular uptake of valsartan with IC50 values (µm) of 39.3 and 20.4, respectively, in MDCK/OATP1B1, while they were less interactive with OATP1B3.",Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663350/),µ,39.3,145477,DB01241,Gemfibrozil
,26663350,IC50 values,"Gemfibrozil and gemfibrozil 1-O-β glucuronide inhibited the cellular uptake of valsartan with IC50 values (µm) of 39.3 and 20.4, respectively, in MDCK/OATP1B1, while they were less interactive with OATP1B3.",Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663350/),µ,20.4,145478,DB01241,Gemfibrozil
,31336317,flow rate,"GFZ was separated on a C18 column using a mixture of 0.01% formic acid and acetonitrile (40:60, v/v) as the mobile phase at a flow rate of 0.4 mL/min.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[ml] / [min],0.4,153069,DB01241,Gemfibrozil
,31336317,area under the plasma concentration versus time curve,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[h·μg] / [ml],88.84,153070,DB01241,Gemfibrozil
,31336317,steady state mean plasma concentration,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[μg] / [ml],7.40,153071,DB01241,Gemfibrozil
,31336317,minimum plasma concentration,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[μg] / [ml],1.24,153072,DB01241,Gemfibrozil
,31336317,maximum plasma concentration,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[μg] / [ml],26.73,153073,DB01241,Gemfibrozil
,31336317,time to reach maximum plasma concentration,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),h,2.28,153074,DB01241,Gemfibrozil
,31336317,elimination half-life,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),h,2.81,153075,DB01241,Gemfibrozil
,31336317,apparent total clearance,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),[l] / [h],7.72,153076,DB01241,Gemfibrozil
,31336317,apparent distribution volume,"The pharmacokinetic parameters are presented as mean (95% CI): area under the plasma concentration versus time curve 88.84 (72.72-104.96) μg·h/mL, steady state mean plasma concentration 7.40 (6.06-8.75) μg/mL, minimum plasma concentration 1.24 (0.87-1.61) μg/mL, maximum plasma concentration 26.73 (21.31-32.15) μg/mL, time to reach maximum plasma concentration 2.28 (1.42-3.13) h, elimination half-life 2.81 (2.22-3.40) h, apparent total clearance 7.72 (5.85-9.58) L/h, apparent distribution volume 33.97 (18.41-49.53) L.",UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31336317/),l,33.97,153077,DB01241,Gemfibrozil
,15373931,half-life,The mean half-life of repaglinide was 1.3 h in all phases.,Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373931/),h,1.3,158397,DB01241,Gemfibrozil
,2381138,maximal plasma levels,"Following oral administration of 900 mg gemfibrozil, maximal plasma levels of the parent drug were 46.1 +/- 15.8 micrograms/ml, attained after 2.2 +/- 1.1 h.",Gemfibrozil absorption and elimination in kidney and liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2381138/),[μg] / [ml],46.1,171987,DB01241,Gemfibrozil
,2381138,elimination half-life,"The elimination half-life of the drug was 1.5 h in controls, 2.4 h in renal failure, and 2.1 h in liver disease.",Gemfibrozil absorption and elimination in kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2381138/),h,1.5,171988,DB01241,Gemfibrozil
,2381138,elimination half-life,"The elimination half-life of the drug was 1.5 h in controls, 2.4 h in renal failure, and 2.1 h in liver disease.",Gemfibrozil absorption and elimination in kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2381138/),h,2.4,171989,DB01241,Gemfibrozil
,2381138,elimination half-life,"The elimination half-life of the drug was 1.5 h in controls, 2.4 h in renal failure, and 2.1 h in liver disease.",Gemfibrozil absorption and elimination in kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2381138/),h,2.1,171990,DB01241,Gemfibrozil
,15487810,AUC0-12,"The mean AUC0-12 of gemfibrozil was 74.7 and 74.1 microg h/ml with and without ezetimibe coadministration, respectively (log-transformed geometric mean ratio (GMR) = 99.2; 90% confidence interval (CI) = 92 - 107%).","Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487810/),[h·μg] / [ml],74.7,179157,DB01241,Gemfibrozil
,15487810,AUC0-12,"The mean AUC0-12 of gemfibrozil was 74.7 and 74.1 microg h/ml with and without ezetimibe coadministration, respectively (log-transformed geometric mean ratio (GMR) = 99.2; 90% confidence interval (CI) = 92 - 107%).","Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15487810/),[h·μg] / [ml],74.1,179158,DB01241,Gemfibrozil
,3481387,peak gemfibrozil concentrations,peak gemfibrozil concentrations (mg/L) were 11.1 (3.9 SD) for the single dose and 10.2 (3.8) for the multiple-dose study.,The effect of renal function on the pharmacokinetics of gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),[mg] / [l],11.1,182104,DB01241,Gemfibrozil
,3481387,peak gemfibrozil concentrations,peak gemfibrozil concentrations (mg/L) were 11.1 (3.9 SD) for the single dose and 10.2 (3.8) for the multiple-dose study.,The effect of renal function on the pharmacokinetics of gemfibrozil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),[mg] / [l],10.2,182105,DB01241,Gemfibrozil
,3481387,Time to peak concentration,"Time to peak concentration (hr) was 2.1 (1.0) and 1.8 (0.6), respectively.",The effect of renal function on the pharmacokinetics of gemfibrozil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),h,2.1,182106,DB01241,Gemfibrozil
,3481387,Time to peak concentration,"Time to peak concentration (hr) was 2.1 (1.0) and 1.8 (0.6), respectively.",The effect of renal function on the pharmacokinetics of gemfibrozil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),h,1.8,182107,DB01241,Gemfibrozil
,3481387,half-life of elimination,"The mean half-life of elimination (hr) from the single-dose study was 6.4 (11.8) compared with the multidose study of 3.0 (3.1), which did not reach statistical significance (P = .25).",The effect of renal function on the pharmacokinetics of gemfibrozil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),h,6.4,182108,DB01241,Gemfibrozil
,3481387,half-life of elimination,"The mean half-life of elimination (hr) from the single-dose study was 6.4 (11.8) compared with the multidose study of 3.0 (3.1), which did not reach statistical significance (P = .25).",The effect of renal function on the pharmacokinetics of gemfibrozil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481387/),h,3.0,182109,DB01241,Gemfibrozil
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01241,Gemfibrozil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,350,194896,DB01241,Gemfibrozil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,20,194897,DB01241,Gemfibrozil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,30,194898,DB01241,Gemfibrozil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,160,194899,DB01241,Gemfibrozil
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,9.0,206726,DB01241,Gemfibrozil
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,35.7,206727,DB01241,Gemfibrozil
,19773540,AUC(bile)/AUC(VH) ratio,"Rosuvastatin was highly transported into bile as shown by the median AUC(bile)/AUC(VH) ratio in TI of 1770 (1640-11,300).",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,1770,206728,DB01241,Gemfibrozil
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.89,206729,DB01241,Gemfibrozil
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.46,206730,DB01241,Gemfibrozil
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],19.9,206788,DB01241,Gemfibrozil
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],17.6,206789,DB01241,Gemfibrozil
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],31.3,206790,DB01241,Gemfibrozil
,15801938,area under the plasma concentration-time curve [AUC((0-infinity))],"Gemfibrozil decreased the mean (+/-SD) area under the plasma concentration-time curve [AUC((0-infinity))] of S-warfarin by 11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P < 0.01) and that of R-warfarin by 6% from 31.3 +/- 7.5 mg l(-1) h during the gemfibrozil phase to 29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P < 0.05).",Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801938/),[h·mg] / [l],29.5,206791,DB01241,Gemfibrozil
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,1.3,210928,DB01241,Gemfibrozil
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,3.7,210929,DB01241,Gemfibrozil
,12687332,t(1/2),"Although itraconazole alone raised repaglinide AUC only 1.4-fold (1.1- to 1.9-fold; p<0.001), the gemfibrozil-itraconazole combination raised it 19.4-fold (12.9- to 24.7-fold) and prolonged the t(1/2) of repaglinide to 6.1 h (p<0.001).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,6.1,210930,DB01241,Gemfibrozil
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,15.8,213950,DB01241,Gemfibrozil
,27259818,Ki,"SVAG was also capable of inhibiting CYP2C8-mediated repaglinide 3'-hydroxylation in human liver microsomes and recombinant human CYP2C8, with Ki values of 15.8 μM and 11.6 μM, respectively.",CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27259818/),μM,11.6,213951,DB01241,Gemfibrozil
,22638872,passive diffusion,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],0.5,215573,DB01241,Gemfibrozil
,22638872,efflux intrinsic clearance,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],1.2,215574,DB01241,Gemfibrozil
,22638872,AUC ratio,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,4.4,215575,DB01241,Gemfibrozil
,22638872,Vs,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,10,215576,DB01241,Gemfibrozil
,9863240,Tmax1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),h,1.10,218905,DB01241,Gemfibrozil
,9863240,Tmax2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),h,2.60,218906,DB01241,Gemfibrozil
,9863240,Cmax1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),[μg] / [ml],13.62,218907,DB01241,Gemfibrozil
,9863240,Cmax2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),[μg] / [ml],17.22,218908,DB01241,Gemfibrozil
,9863240,T1,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),h,0.06,218909,DB01241,Gemfibrozil
,9863240,T2,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),h,1.42,218910,DB01241,Gemfibrozil
,9863240,T3,"The corresponding pharmacokinetic parameters were estimated as follows: Tmax1, 1.10 +/- 0.46 h; Tmax2, 2.60 +/- 0.73 h; Cmax1, 13.62 +/- 4.30 micrograms.ml-1; Cmax2, 17.22 +/- 3.83 micrograms.ml-1; T1, 0.06 +/- 0.06 h; T2, 1.42 +/- 0.57 h and T3, 1.79 +/- 0.60 h.",[Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863240/),h,1.79,218911,DB01241,Gemfibrozil
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.1,220867,DB01241,Gemfibrozil
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.3,220868,DB01241,Gemfibrozil
,8886608,flow rate,"Using a recirculating design, erythrocyte-free perfusion medium containing 1% (w/v) albumin was delivered to the liver via the portal vein at a flow rate of 30 ml/min, and for each experiment was spiked with either gemfibrozil (N = 4) or 1-O-gemfibrozil-beta-D-glucuronide (N = 4) at initial concentrations of 120 microM and 21 microM, respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),[ml] / [min],30,224649,DB01241,Gemfibrozil
,8886608,total perfusate clearance,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),[ml] / [min],2.73,224650,DB01241,Gemfibrozil
,8886608,half-life,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),min,76.9,224651,DB01241,Gemfibrozil
,8886608,half-life,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.091,224652,DB01241,Gemfibrozil
,8886608,hepatic extraction ratio,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),min,76.9,224653,DB01241,Gemfibrozil
,8886608,fraction of eliminated,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),min,76.9,224654,DB01241,Gemfibrozil
,8886608,fraction of eliminated,"In the gemfibrozil perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio of gemfibrozil, and the fraction of eliminated gemfibrozil excreted in bile as the glucuronide conjugate were 2.73 (0.30) ml/min, 76.9 (5.6) min, 0.091 (0.012), and 0.347 (0.154), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.347,224655,DB01241,Gemfibrozil
,8886608,total perfusate clearance,"In the 1-O-gemfibrozil-beta-D-glucuronide perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio, and fraction excreted in bile as the glucuronide conjugate were 19.5 (2.1) ml/min, 8.7 (0.9) min, 0.649 (0.068), and 0.534 (0.077), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),[ml] / [min],19.5,224656,DB01241,Gemfibrozil
,8886608,half-life,"In the 1-O-gemfibrozil-beta-D-glucuronide perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio, and fraction excreted in bile as the glucuronide conjugate were 19.5 (2.1) ml/min, 8.7 (0.9) min, 0.649 (0.068), and 0.534 (0.077), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),min,8.7,224657,DB01241,Gemfibrozil
,8886608,half-life,"In the 1-O-gemfibrozil-beta-D-glucuronide perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio, and fraction excreted in bile as the glucuronide conjugate were 19.5 (2.1) ml/min, 8.7 (0.9) min, 0.649 (0.068), and 0.534 (0.077), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.649,224658,DB01241,Gemfibrozil
,8886608,hepatic extraction ratio,"In the 1-O-gemfibrozil-beta-D-glucuronide perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio, and fraction excreted in bile as the glucuronide conjugate were 19.5 (2.1) ml/min, 8.7 (0.9) min, 0.649 (0.068), and 0.534 (0.077), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),min,8.7,224659,DB01241,Gemfibrozil
,8886608,fraction excreted in bile,"In the 1-O-gemfibrozil-beta-D-glucuronide perfusions, the mean (SD) total perfusate clearance, half-life, hepatic extraction ratio, and fraction excreted in bile as the glucuronide conjugate were 19.5 (2.1) ml/min, 8.7 (0.9) min, 0.649 (0.068), and 0.534 (0.077), respectively.",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.534,224660,DB01241,Gemfibrozil
,8886608,unbound fraction,"The higher hepatic extraction ratio for 1-O-gemfibrozil-beta-D-glucuronide could mostly be attributed to its higher unbound fraction in perfusate (0.182), compared with that of the parent drug (0.004), because the conjugate had a lower intrinsic clearance (305 ml/min) compared with the aglycone (751 ml/min).",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.182,224661,DB01241,Gemfibrozil
,8886608,unbound fraction,"The higher hepatic extraction ratio for 1-O-gemfibrozil-beta-D-glucuronide could mostly be attributed to its higher unbound fraction in perfusate (0.182), compared with that of the parent drug (0.004), because the conjugate had a lower intrinsic clearance (305 ml/min) compared with the aglycone (751 ml/min).",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),,0.,224662,DB01241,Gemfibrozil
,8886608,intrinsic clearance,"The higher hepatic extraction ratio for 1-O-gemfibrozil-beta-D-glucuronide could mostly be attributed to its higher unbound fraction in perfusate (0.182), compared with that of the parent drug (0.004), because the conjugate had a lower intrinsic clearance (305 ml/min) compared with the aglycone (751 ml/min).",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),[ml] / [min],305,224663,DB01241,Gemfibrozil
,8886608,intrinsic clearance,"The higher hepatic extraction ratio for 1-O-gemfibrozil-beta-D-glucuronide could mostly be attributed to its higher unbound fraction in perfusate (0.182), compared with that of the parent drug (0.004), because the conjugate had a lower intrinsic clearance (305 ml/min) compared with the aglycone (751 ml/min).",Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8886608/),[ml] / [min],751,224664,DB01241,Gemfibrozil
,10872583,limits of detection,"The limits of detection for the covalent adducts in human plasma are: 10 ng ml(-1) (GEM), 20 ng ml(-1) (M1), 0.5 ng ml(-1) (M2, M4), and 5 ng ml(-1) (M3).","Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872583/),[ng] / [ml],10,230728,DB01241,Gemfibrozil
,10872583,limits of detection,"The limits of detection for the covalent adducts in human plasma are: 10 ng ml(-1) (GEM), 20 ng ml(-1) (M1), 0.5 ng ml(-1) (M2, M4), and 5 ng ml(-1) (M3).","Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872583/),[ng] / [ml],20,230729,DB01241,Gemfibrozil
,10872583,limits of detection,"The limits of detection for the covalent adducts in human plasma are: 10 ng ml(-1) (GEM), 20 ng ml(-1) (M1), 0.5 ng ml(-1) (M2, M4), and 5 ng ml(-1) (M3).","Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872583/),[ng] / [ml],0.5,230730,DB01241,Gemfibrozil
,10872583,limits of detection,"The limits of detection for the covalent adducts in human plasma are: 10 ng ml(-1) (GEM), 20 ng ml(-1) (M1), 0.5 ng ml(-1) (M2, M4), and 5 ng ml(-1) (M3).","Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872583/),[ng] / [ml],5,230731,DB01241,Gemfibrozil
,18388877,half-life,"The peak repaglinide concentration increased approximately twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.",The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18388877/),h,1.2,237169,DB01241,Gemfibrozil
,18388877,half-life,"The peak repaglinide concentration increased approximately twofold (P < 0.001), and the half-life was prolonged from 1.2 h to 2-3 h (P < 0.001) during all the gemfibrozil phases.",The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18388877/),h,2-3,237170,DB01241,Gemfibrozil
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238835,DB01241,Gemfibrozil
,16028010,irreversible elimination clearances,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238836,DB01241,Gemfibrozil
,16028010,CL10,"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238837,DB01241,Gemfibrozil
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],10.5,238838,DB01241,Gemfibrozil
,16028010,CL20),"In control animals, the irreversible elimination clearances of SV (CL10) and SVA (CL20) were 10.5 and 18.6 ml min(-1) kg(-1), respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],18.6,238839,DB01241,Gemfibrozil
,16028010,CL12,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],4.8,238840,DB01241,Gemfibrozil
,16028010,CL21,"The formation clearance of SVA from SV (CL12 = 4.8 ml min(-1) kg(-1)) was 8-fold greater than that of SV from SVA (CL21 = 0.6 ml min(-1) kg(-1)), and the recycled fraction was relatively minor (0.009).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.6,238841,DB01241,Gemfibrozil
,16028010,CL,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238842,DB01241,Gemfibrozil
,16028010,CL12,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],2.9,238843,DB01241,Gemfibrozil
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238844,DB01241,Gemfibrozil
,16028010,CL20,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238845,DB01241,Gemfibrozil
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],9,238846,DB01241,Gemfibrozil
,16028010,CL21,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238847,DB01241,Gemfibrozil
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[ml] / [kg·min],0.14,238848,DB01241,Gemfibrozil
,16028010,recycled fraction,"In gemfibrozil-treated animals, CL10 was essentially unchanged, whereas CL12, CL20, CL21, and recycled fraction were significantly decreased to 2.9, 9, 0.14 ml min(-1) kg(-1), and 0.003, respectively.",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),,0.00,238849,DB01241,Gemfibrozil
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],2.3,238850,DB01241,Gemfibrozil
,16028010,"volume of distribution at steady state (Vss,real)","In control dogs, values for real volume of distribution at steady state (Vss,real) of SV (2.3 L kg(-1)) were much larger than the corresponding values of SVA (0.3 L kg(-1)).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),[l] / [kg],0.3,238851,DB01241,Gemfibrozil
>,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,200,238852,DB01241,Gemfibrozil
,16028010,IC5),"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,100,238853,DB01241,Gemfibrozil
,16028010,IC50,"In dog hepatocytes, gemfibrozil modestly affected the formation of CYP3A-mediated oxidative metabolites (IC50 > 200 microM) and beta-oxidative products (IC5) approximately 100 microM), but markedly inhibited the glucuronidation-mediated lactonization of SVA and the glucuronidation of an SVA beta-oxidation product (IC50 = 18 microM).",Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16028010/),μM,18,238854,DB01241,Gemfibrozil
,19773535,turnover half-life,"Based on the recovery of repaglinide oral clearance, the in vivo turnover half-life of CYP2C8 was estimated to average 22 +/- 6 h (mean +/- S.D.).",CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773535/),h,22,240272,DB01241,Gemfibrozil
,14531725,oral bioavailability,"However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.",Clinical pharmacokinetics of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,14,249256,DB01241,Gemfibrozil
,14531725,volume of distribution,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),l,381,249257,DB01241,Gemfibrozil
exceeds,14531725,plasma protein binding,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,98,249258,DB01241,Gemfibrozil
,14531725,total plasma clearance,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),[ml] / [min],625,249259,DB01241,Gemfibrozil
,14531725,half-life,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),h,7,249260,DB01241,Gemfibrozil
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,289,264658,DB01241,Gemfibrozil
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,130,264659,DB01241,Gemfibrozil
,21466853,half-life,"Using the Arrhenius equation, the extrapolated half-life at 37°C were 289 days at pH 1.2 for the codrug and 130 and 20,315 days at pH 6.8 for the codrug and gemfibrozil 2-hydroxyethyl ester (GHEE), respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,"20,315",264660,DB01241,Gemfibrozil
,21466853,half-lives,"The shortest half-lives were at pH 7.4; 42 days for the codrug and 5837 days for GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,42,264661,DB01241,Gemfibrozil
,21466853,half-lives,"The shortest half-lives were at pH 7.4; 42 days for the codrug and 5837 days for GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),d,5837,264662,DB01241,Gemfibrozil
,21466853,k(obs),The k(obs) was found in both cases to be 1.60×10(-3)h(-1).,"Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),1/[h],1.60×10(-3),264663,DB01241,Gemfibrozil
,21466853,half-lives,"The half-lives in plasma were 35.24 min and 26.75 h for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,35.24,264664,DB01241,Gemfibrozil
,21466853,half-lives,"The half-lives in plasma were 35.24 min and 26.75 h for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),h,26.75,264665,DB01241,Gemfibrozil
,21466853,hydrolysis half-lives,"With regard to liver homogenate, the hydrolysis half-lives were 1.96 min and 48.13 min for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,1.96,264666,DB01241,Gemfibrozil
,21466853,hydrolysis half-lives,"With regard to liver homogenate, the hydrolysis half-lives were 1.96 min and 48.13 min for the codrug and GHEE, respectively.","Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466853/),min,48.13,264667,DB01241,Gemfibrozil
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,21,267874,DB01241,Gemfibrozil
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,1.,267875,DB01241,Gemfibrozil
,8565777,steady-state concentrations,Plasma was quantitatively the most important site for formation of gemfibrozil-protein adducts with mean (SE) steady-state concentrations of 31.40 (2.40) ng/mg protein attained by approximately the 10th day of dosing.,Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8565777/),[ng] / [mg],31.40,272505,DB01241,Gemfibrozil
,8565777,half-life,"Adduct half-life in plasma was 3.1 days, consistent with the elimination half-life of albumin.",Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8565777/),d,3.1,272506,DB01241,Gemfibrozil
,8565777,steady-state adduct concentrations,"Mean (SE) kidney, liver, and heart steady-state adduct concentrations were 2.13 (0.11), 0.89 (0.35), and 0.95 (0.07) ng/mg protein, respectively.",Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8565777/),[ng] / [mg],2.13,272507,DB01241,Gemfibrozil
,8565777,steady-state adduct concentrations,"Mean (SE) kidney, liver, and heart steady-state adduct concentrations were 2.13 (0.11), 0.89 (0.35), and 0.95 (0.07) ng/mg protein, respectively.",Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8565777/),[ng] / [mg],0.89,272508,DB01241,Gemfibrozil
,8565777,steady-state adduct concentrations,"Mean (SE) kidney, liver, and heart steady-state adduct concentrations were 2.13 (0.11), 0.89 (0.35), and 0.95 (0.07) ng/mg protein, respectively.",Reactivity of gemfibrozil 1-o-beta-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8565777/),[ng] / [mg],0.95,272509,DB01241,Gemfibrozil
